Stability of ganciclovir in extemporaneously compounded oral liquids

被引:6
作者
Anaizi, NH
Swenson, CF
Dentinger, PJ
机构
[1] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharm, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA
[3] Strong Mem Hosp, Dept Pharm, Rochester, NY USA
关键词
antivirals; compounding; containers; formulations; ganciclovir sodium; incompatibilities; liquids; polyethylene terephthalate; stability; storage; sweetening agents;
D O I
10.1093/ajhp/56.17.1738
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of ganciclovir in extemporaneously prepared sugar-containing and sugar-free oral liquids was studied. The contents of 80 250-mg capsules of ganciclovir were combined with Ora-Sweet or Ora-Sweet SF (sugar free) (Paddock Laboratories) to produce 200 mL of suspension with a ganciclovir concentration of 100 mg/mL. Five 1-mL samples were analyzed immediately, and the rest of the suspension was poured into five 60-mL amber polyethylene terephthalate bottles and stored at 23-25 degrees C. Samples were removed and analyzed with stability-indicating highperformance liquid chromatography on days 15, 35, 60, 91, and 123. The suspensions retained at least 96% of the initial ganciclovir concentration for 123 days. The pH of the suspensions was initially 4.5 and remained unchanged throughout the study. There was no detectable change in color or odor and no visible microbial growth in any sample. Ganciclovir 100 mg/mL was stable for 123 days in sugar-containing and sugar-free oral liquids stored at 23-25 degrees C in amber polyethylene terephthalate bottles.
引用
收藏
页码:1738 / 1741
页数:4
相关论文
共 11 条
[1]  
Ahsan N, 1997, CLIN TRANSPLANT, V11, P633
[2]   INSTABILITY OF AQUEOUS CAPTOPRIL SOLUTIONS [J].
ANAIZI, NH ;
SWENSON, C .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1993, 50 (03) :486-488
[3]   Drug therapy - Ganciclovir [J].
Crumpacker, CS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :721-729
[4]   Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics [J].
Filler, G ;
Lampe, D ;
von Bredow, MA ;
Lappenberg-Pelzer, M ;
Rocher, S ;
Strehlau, J ;
Ehrich, JHH .
PEDIATRIC NEPHROLOGY, 1998, 12 (01) :6-9
[5]   Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [J].
Gane, E ;
Saliba, F ;
Valdecasas, GJC ;
OGrady, J ;
Pescovitz, MD ;
Lyman, S ;
Robinson, CA .
LANCET, 1997, 350 (9093) :1729-1733
[6]   Management of cytomegalovirus infection after solid-organ or stem-cell transplantation - Current guidelines and future prospects [J].
Hebart, H ;
Kanz, L ;
Jahn, G ;
Einsele, H .
DRUGS, 1998, 55 (01) :59-72
[7]   Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) [J].
Moxey-Mims, MM ;
Kay, C ;
Light, JA ;
Kher, KK .
TRANSPLANTATION, 1998, 65 (05) :617-619
[8]   STABILITY OF GANCICLOVIR SODIUM IN 5-PERCENT DEXTROSE INJECTION AND IN 0.9-PERCENT SODIUM-CHLORIDE INJECTION OVER 35 DAYS [J].
PARASRAMPURIA, J ;
LI, LC ;
STELMACH, AH ;
SYKES, TR ;
GORDON, GA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (01) :116-118
[9]  
Roth D, 1998, TRANSPLANTATION, V65, P248
[10]   STABILITY AND COMPATIBILITY OF GANCICLOVIR SODIUM IN 5-PERCENT DEXTROSE INJECTION OVER 35 DAYS [J].
SILVESTRI, AP ;
MITRANO, FP ;
BAPTISTA, RJ ;
WILLIAMS, DA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1991, 48 (12) :2641-2643